Results 211 to 220 of about 14,958,381 (308)

Quality of Life and Primary Open-Angle Glaucoma in the Ocular Hypertension Treatment Study.

JAMA Ophthalmol
Gordon MO, Gao F, Burkland J, Huecker JB, Gardiner SK, Ramulu P, Zangwill LM, Heuer DK, Higginbotham EJ, Parrish RK, Kass MA.   +10 more
europepmc   +1 more source

Implementation of recommended treatment for children in weight management programs: Lessons from the stay in treatment study sites. [PDF]

Prev Med
Fleischman A, Hampl S, Rhodes ET, Sweeney B, Eneli I, Skelton JA.   +5 more
europepmc   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Last Study Treatment Time [PDF]

, 2020
openaire   +1 more source

Infographic: the glaucoma intensive treatment study (GITS): a randomized controlled trial comparing intensive and standard treatment on 5 years visual field development. [PDF]

Eye (Lond)
Alkhusheh A, Noor MA.
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

PROGRESS: A patient-centered engagement infrastructure and multi-level approach to enrich diversity, equity, and inclusion in a national randomized online behavioral pain treatment study. [PDF]

J Pain
Clifton J, Adair E, Cheung M, Torres C, Andrews W, Dorsonne B, Hailu AY, Heggan E, Miefert J, Riazi G, Dildine TC, Spears S, Greer-Smith R, Pun T, Williams N, Perez L, King HP, Ziadni MS, Mackey S, Darnall BD.   +19 more
europepmc   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Visual field progression patterns in the ocular hypertension treatment study correspond to vulnerability regions of the disc. [PDF]

Eye (Lond)
Leshno A, Bommakanti N, De Moraes CG, Gordon MO, Kass MA, Cioffi GA, Liebmann JM.   +6 more
europepmc   +1 more source